Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05686226 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05686226 · ClinicalTrials.gov record · last posted 2026-06-12

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

StatusRecruiting
PhasePhase 2
Started2023-03-07
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers. HPV-associated cancers in include cervical, throat, penile, vulvar, vaginal, anal, and other cancers. Participants will receive a conditioning regimen, E7 TCR-T cells, and aldesleukin. Clinical response to treatment will be determined.

Amendment record 7 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 7 times since 2023-01-08; most recent amendment 2026-06-10. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2023-03-24
Status change Not Yet Recruiting→Recruitingv2
Trial Details
NCT Number NCT05686226
Lead Sponsor Christian Hinrichs
Collaborators: National Cancer Institute (NCI), Iovance Biotherapeutics, Inc.
Conditions Cervical Cancer, Throat Cancer, Oropharynx Cancer, Anal Cancer, Vulva Cancer, Vaginal Cancer, Penile Cancer, Metastatic Cancer +13 more
Enrollment 20 participants
Start Date 2023-03-07
Primary Completion 2027-01-01 (estimated)
Study Completion 2027-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-12